CTIS2023-509019-97-00进行中(未招募)1 期
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multi-centre study to assess the tolerability and efficacy of the addition of hydroxyurea to standard ara-C and daunorubicin-based therapy for adults (age = 18 years of age) with newly diagnosed acute myeloid leukaemia (AML)
Karolinska University Hospital0 个研究点目标入组 69 人开始时间: 2024年2月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •diagnosis of AML and related myeloid precursor neoplasia according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or acute leukaemia of ambiguous lineage according to WHO 2008, Patients 18 years and older., Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: Serum creatinine = 220 µmol/L, unless considered AML-related; Serum bilirubin = 2.5 x upper limit of normal (ULN, i.e. =65 µmol/L), unless considered AML-related or due to Gilbert's syndrome; Alanine aminotransferase (ALAT) = 2.5 x ULN, i.e. = 1.9 µcat/L and = 2.9 for females and males, respectively, unless considered AML-related, Male patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment., Written informed consent., Patient is capable of giving informed consent.
排除标准
- •Acute promyelocytic leukemia., Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance., CNS leukaemia, Ongoing treatment with gemtuzumab-ozogamicin., Major organ failure precluding administration of planned chemotherapy., Glomerular filtration rate (GFR) < 30 ml/min, Cardiac dysfunction as defined by: Myocardial infarction within the last 3 months of study entry, or; Reduced left ventricular function with an ejection fraction < 40% as measured by echocardiogram (will only be performed when clinically suspected) or; Unstable angina or; New York Heart Association (NYHA) grade IV congestive heart failure or; Unstable cardiac arrhythmias, Known intolerance to any of the chemotherapeutic drugs in the protocol., Positive pregnancy test. Lactating female or female of childbearing potential not using adequate contraception., Fanconi anaemia
研究者
相似试验
进行中(未招募)
1 期
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea to standard treatment against acute myeloid leukaemia (AML) is safe and efficaciousEUCTR2018-004050-16-SEniversity Hospital Karolinska69
进行中(未招募)
1 期
A clinical trial to evaluate the safety and efficacy for patients with localregional relapse in breast cancer scheduled to be treated with radiotherapy, hyperthermia and Lyso-Thermosenstive Liposomal DoxorubiciEUCTR2015-000167-14-ITCELSION CORPORATIO70
已完成
不适用
Phase one clinical trials of hyperthermia using radiofrequency capacitive heating device and magnetic cationic liposome in prostate cancer resistant to standard treatmentprostate cancerJPRN-UMIN000021187agoya City University Hospital3
已完成
不适用
Anti-Xa trough levels for therapeutic LMWH treatment monitoring, a pilot studyVTE venous tromboembolic events en Atriumfibrillation10014523NL-OMON49087Sint Antonius Ziekenhuis30
进行中(未招募)
1 期
HBOT LYCA: exploring if pressurechamber treatment can reduce lymphoedema after breast cancerEUCTR2015-000604-25-DKDanish Cancer Society Research Center25
